Private biotech
Appears in 1 story · Last updated Sep 14, 2026
As of September 2026: Developer of Tam-Peli; holds Greater China rights, ex-China licensed to Roche
Two rival antibody-drug conjugates just beat the standard of care in relapsed small-cell lung cancer. Roche-partnered Tam-Peli held median survival at 13.3 months; GSK's competitor got 18.5. Both faced the same decades-old chemotherapy — and that five-month gap is the story.
Updated Sep 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
